《WHO人类医学重要抗菌药物清单》

  • 来源专题:新发突发传染病
  • 发布时间:2024-02-20
  • The responsible and prudent use of antimicrobials needs to be improved in all sectors - human, animal, plant/crop, and environment - to preserve their public health benefits. In particular, antimicrobials that are medically important for human medicine need to be preserved by reducing their use in the non-human sectors. The WHO list of medically important antimicrobials for human medicine (WHO MIA List) is a risk management tool that can be used to support decision-making to minimize the impact of antimicrobial use in non-human sectors on antimicrobial resistance (AMR) in humans. The WHO MIA List is created to guide international, national, and subnational (local, state, provincial) antimicrobial stewardship efforts. It complements the WHO AWaRe (Access, Watch, Reserve) framework and antibiotic book which provide guidance on appropriate use of essential antibiotics within the human health sector.

    The list categorizes antimicrobial classes based on their importance for human medicine and according to the AMR risk and potential human health implications of their use in non-human sectors: critically important, highly important, and important to human medicine. The publication is intended to serve as a reference tool to support decision-making by national regulators and policymakers in ministries of health and agriculture, authorities responsible for regulating, monitoring, and assuring the responsible and prudent use of antimicrobials, and professional prescribers in different sectors.

    The WHO MIA List was developed in close collaboration with the Food and Agriculture Organization (FAO), the United Nations Environmental Programme (UNEP) and the World Organisation for Animal Health (WOAH) as a joint effort to harmonize and align related guidance and lists developed by the four organizations. Best practice statements included in the document are aligned with the position of the Quadripartite organizations (FAO, UNEP, WHO, and WOAH) and are critical to preserving the effectiveness of the agents in the WHO MIA List. Further work is ongoing to harmonize guidance on the prudent use of antimicrobials across all four organizations and this WHO antimicrobial list and the WOAH List of antimicrobial agents of veterinary importance.

    AMR remains one of the top global public health threats facing humanity and was associated with the death of close to 5 million people globally in 2019. AMR occurs when bacteria, viruses, fungi, and parasites change over time and no longer respond to antimicrobial medicines making infections harder to treat and increasing the risk of disease spread, severe illness, and death. As a result, antimicrobial medicines become ineffective and infections persist in the body, increasing the risk of transmission to others. The WHO MIA List supports the optimized use of antimicrobial medicines in human and animal health.

相关报告
  • 《2017年欧盟关于人类、动物和食物中人畜共患病和细菌抗菌素耐药性的总结报告》

    • 来源专题:动植物疫病
    • 发布时间:2019-03-15
    • The data on antimicrobial resistance in zoonotic and indicator bacteria in 2017, submitted by 28 EU Member States (MSs), were jointly analysed by EFSA and ECDC. Resistance in zoonotic Salmonella and Campylobacter from humans, animals and food, and resistance in indicator Escherichia coli as well as meticillin-resistant Staphylococcus aureus in animals and food were addressed, and temporal trends assessed. ‘Microbiological’ resistance was assessed using epidemiological cut-off (ECOFF) values; for some countries, qualitative data on human isolates were interpreted in a way which corresponds closely to the ECOFF-de?ned ‘microbiological’ resistance.
  • 《抗菌剂消耗—2016年年度流行病学报告》

    • 来源专题:动植物疫病
    • 发布时间:2018-12-05
    • 本报告基于2018年2月19日从欧洲监测系统(TESSy)检索的2016年数据。 (1)有29个国家,其中包括27个欧盟成员国和2个欧洲经济区国家(冰岛和挪威)报道了社区,即外部医院的抗菌药物消耗数据。另外,有23个国家报道了2016年医院部门的消耗数据。 (2)根据各个社区的统计,2016年全身性抗菌药物使用(解剖治疗化学组J01,ATC)的平均消费量是每1000名居民使用21.9DDD(国家范围:10.4~36.6)。在2012-2016年期间,欧盟/欧洲经济区的使用统计整体上没有显著变化。但是,希腊和西班牙的使用统计上呈现显著的增长趋势,而芬兰、卢森堡、挪威和瑞典的使用统计上呈现显著的下降趋势。 (3)社区里全身性抗霉菌真菌药物使用(ATC组J02和D01B)的平均消费量是每天每1000居民使用1.0DDD(国家范围:0.37~3.1)。 (4)根据医院的使用统计,全身性抗菌药物使用的平均消费量是每天每1000名居民使用2.1DDD(国家范围:1.0~2.9)。在2012-2016年期间,欧盟/欧洲经济区的使用统计整体上没有显著变化。但是,希腊、马耳他和斯洛文尼亚的使用统计上呈现显著的增长趋势,并且爱沙尼亚、芬兰和卢森堡的使用统计上呈现显著的下降趋势。 (5)碳青霉烯类药物的平均消费量是每天每1000居民使用0.05DDD(国家范围:0.03~0.18),在2012年至2016年期间它的使用没有显著性变化。但是,其中有10个国家的使用统计上呈现显著的增长趋势,同一时期有另一个国家的使用统计上呈现显著的下降趋势。 (6)多粘菌素的平均消费量是每天每1000居民使用0.015DDD(国家范围:<0.001~0.102),并且在2012年至2016年期间它的使用没有显著性变化。不过,其中有9个国家的使用统计上呈现显著的增长趋势,也有两个国家的使用统计上呈现显著的下降趋势。 (7)全身性抗霉菌真菌药物使用(ATC组J02和D01B)的平均消费量是每天每1000名居民使用0.06DDD(国家范围:0.02~0.18)。 (8)2016年,两个部门(社区和医院)的全身性抗病毒药物使用(ATC组J05)的平均消费量是每天每1000居民使用3.0DDD(国家范围:0.21~7.4)。 该报告主要包括关键事实、方法、抗菌消耗数据统计和讨论几个部分。